BioSim™ - ELISA Kits for BioSimilar Antibodies

October 2017  |  Press Releases

BioSim™ - ELISA Kits for BioSimilar Antibodies


MILPITAS, Calif. - Oct. 18, 2017 - PRLog -- Human IgG based monoclonal antibodies (mAbs) are the fastest-growing category of therapeutics for cancer therapy. Several monoclonal antibodies have received FDA approval for the treatment of a variety of solid tumors and hematological malignancies. Several mechanisms of tumor cell killing by antibodies (mAbs) can be summarized as: direct action through receptor blockade or induction of apoptosis; immune-mediated cell killing by complement-dependent cytotoxicity (CDC), antibody-dependent cellular cytotoxicity (ADCC) or regulation of T cell function. BioVision is pleased to offer one of the largest selections of ELISA Kits for research-grade biosimilar antibodies. These ELISA Kits can be used to study dose-pendent pharmacokinetics as well as to identify biomarkers for (non-)response and risk factors for adverse drug reactions.

Typical Standard Curve for Rituximab ELISA Kit (E4371)

Key Features:

• Rapid and Simple: No expensive equipment or special handling/disposal required
• Accurate: Reproducible results with low intra & inter assay variability
• Highly Sensitive and Specific

We have research grade Biosimilar antibodies and ELISA kits for Adlimumab, Bevazumab, Cetuximab and many many more.

Click here to see all the Antibodies and ELISA Kits for BioSimilar antibodies from BioVision

About BioVision:

BioVision, Inc. is a privately held Life Science company headquartered in the beautiful San Francisco Bay area. BioVision develops and offers a wide variety of products including assay kits, antibodies, recombinant proteins & enzymes, and other innovative research tools for studying Apoptosis, Metabolism, Cell Proliferation, Cellular Stress, Cell Damage and Repair, Diabetes, Obesity and Metabolic Syndrome, Stem Cell Biology, Gene Regulation, Signal Transduction, and more.